Immunocore Holdings plc (IMCR): who owns it and who trades it
As of Nov 16, 2026, IMCR insiders reported 10 open-market sales worth $5.6M and no purchases in the last 12 months, with 89% of the sale value made under pre-set 10b5-1 plans. The largest seller was David M Berman (HEAD OF R&D), with $5.2M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Immunocore Holdings
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds and famous investors were close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IMCR
136 funds and institutions reported IMCR shares worth $1.7B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Wellington Management Group LLP with 11.2%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Wellington Management Group LLP | 5.72M | 11.25% | $182M | +22% |
| Rtw Investments, LP | 4.87M | 9.57% | $155M | No change |
| FMR LLC (Fidelity) | 4.31M | 8.47% | $137M | -11% |
| Primecap Management Co | 3.64M | 7.15% | $116M | -1% |
| Bellevue Group AG | 2.79M | 5.48% | $88.5M | -0% |
| Tang Capital Management LLC | 2.65M | 5.21% | $84.1M | No change |
| Vestal Point Capital, LP | 1.80M | 3.54% | $57.1M | -35% |
| Two Sigma Investments, LP | 1.65M | 3.24% | $52.4M | +61% |
| Millennium Management LLC | 1.60M | 3.14% | $50.7M | +29% |
| Armistice Capital, LLC | 1.43M | 2.81% | $45.3M | +20% |
| Caligan Partners LP | 1.38M | 2.72% | $43.9M | – |
| Kynam Capital Management, LP | 1.38M | 2.70% | $43.7M | +55% |
| Bvf Inc | 1.29M | 2.54% | $41.1M | No change |
| Acadian Asset Management LLC | 1.21M | 2.38% | $38.4M | +141% |
| Trails Edge Capital Partners, LP | 1.06M | 2.09% | $33.8M | +56% |
| BlackRock, Inc. | 1.00M | 1.98% | $31.9M | +53% |
| Point72 Asset Management, L.P. | 990,280 | 1.95% | $31.4M | -10% |
| T. Rowe Price Associates | 831,068 | 1.63% | $26.4M | -10% |
| Jupiter Topco LLC | 709,022 | 1.39% | $22.5M | – |
| Cantor Fitzgerald, L. P. | 680,200 | 1.34% | $21.6M | +172% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, IMCR insiders reported $0 of open-market purchases and $5.6M of sales. 89% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | Bahija Jallal | CEO | Sale | 11,474 | $32.35 | $371K | Form 4 |
| Feb 18, 2026 | John Goll | Vice president | Sale | 698 | $32.35 | $22.6K | Form 4 |
| Feb 18, 2026 | Leger Tina Amber St | CHIEF HR OFFICER | Sale | 1,000 | $32.35 | $32.4K | Form 4 |
| Feb 18, 2026 | David M Berman | HEAD OF R&D | Sale | 5,965 | $32.35 | $193K | Form 4 |
| Dec 5, 2025 | David M Berman | HEAD OF R&D | Sale plan | 572 | $40.14 | $23K | Form 4 |
| Dec 4, 2025 | David M Berman | HEAD OF R&D | Sale plan | 31,341 | $40.26 | $1.3M | Form 4 |
| Nov 28, 2025 | David M Berman | HEAD OF R&D | Sale plan | 5,521 | $40.09 | $221K | Form 4 |
| Nov 26, 2025 | David M Berman | HEAD OF R&D | Sale plan | 69,404 | $40.12 | $2.8M | Form 4 |
| Nov 25, 2025 | David M Berman | HEAD OF R&D | Sale plan | 18,020 | $40.03 | $721K | Form 4 |
| Nov 24, 2025 | David M Berman | HEAD OF R&D | Sale plan | 100 | $40.00 | $4K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| David M Berman | HEAD OF R&D | – | $5.2M | Feb 18, 2026 |
| Bahija Jallal | CHIEF EXECUTIVE OFFICER, Director | – | $371K | Feb 18, 2026 |
| Leger Tina Amber St | CHIEF HR OFFICER | – | $32.4K | Feb 18, 2026 |
| John Goll | SVP, FINANCE & CAO | – | $22.6K | Feb 18, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IMCR short interest
High short interest. 15.1% of IMCR shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went down 13%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 7.79M IMCR shares were sold short, 15.1% of the shares outstanding, down 0.1% from the report before. At the average daily volume of 548,595 shares, buying them all back would take about 14.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 7.79M | 15.13% | -0% | 548,595 | 14.2 |
| Oct 15, 2026 | 7.80M | 15.15% | -1% | 498,403 | 15.7 |
| Sep 30, 2026 | 7.90M | 15.35% | +2% | 381,726 | 20.7 |
| Sep 15, 2026 | 7.77M | 15.09% | -0% | 377,893 | 20.6 |
| Aug 31, 2026 | 7.79M | 15.13% | -1% | 374,592 | 20.8 |
| Aug 14, 2026 | 7.90M | 15.33% | -4% | 420,023 | 18.8 |
| Jul 31, 2026 | 8.22M | 15.96% | -8% | 472,941 | 17.4 |
| Jul 15, 2026 | 8.94M | 17.58% | -1% | 707,799 | 12.6 |
| Jun 30, 2026 | 8.99M | 17.68% | -1% | 718,644 | 12.5 |
| Jun 15, 2026 | 9.04M | 17.77% | +3% | 423,008 | 21.4 |
| May 29, 2026 | 8.75M | 17.20% | -2% | 443,958 | 19.7 |
| May 15, 2026 | 8.97M | 17.64% | No change | 253,399 | 35.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Immunocore Holdings company events
Immunocore Holdings filed 9 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 6, 2026.
- Nov 6, 2026ResultsReleased financial results. Filing
- Sep 14, 2026AnnouncementShared information with investors. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- May 27, 2026VoteReported shareholder vote results. Filing
- May 6, 2026ResultsReleased financial results. Filing
- Feb 25, 2026ResultsReleased financial results. Filing
- Jan 30, 2026LeadershipDavid Berman notified Immunocore Holdings plc of his decision to resign as Head of Research & Development of the Company, effective as of February 27, 2026, in order to pursue another opportunity. Filing
- Jan 9, 2026AnnouncementThe Company published an updated pipeline chart of KIMMRAK (tebentafusp) and its therapeutic candidates in development, which is filed as Exhibit 99.3 to this Current Report on Form 8-K and incorporated by reference herein. Filing
- Nov 28, 2025LeadershipRanjeev Krishana notified the board of directors of Immunocore Holdings plc of his decision to resign as a member of the Board and a member of the Remuneration Committee of the Board, effective immediately. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Immunocore Holdings financials
Famous investors that hold IMCR
4 of the 50 well-known investors we track reported holding IMCR in their latest 13F filing. The largest position is Steve Cohen's, worth $38.1M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.26M | $38.1M | 0.1% | +27% |
| Israel Englander · Millennium Management | Q3 2026 | 839,258 | $25.4M | 0.0% | -47% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 267,325 | $8.1M | 0.0% | -53% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 267,200 | $8.1M | 0.0% | +161% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named IMCR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Bellevue Group AG | 13G/A | 4.4% |
| Nov 16, 2026 | Bellevue Group AG | 13G/A | 4.4% |
| Nov 9, 2026 | Point72 Asset Management, L.P. | 13G | 5.2% |
| Nov 9, 2026 | Point72 Asset Management, L.P. | 13G | 5.2% |
| Oct 7, 2026 | FMR LLC | 13G/A | 3.6% |
| Oct 7, 2026 | FMR LLC | 13G/A | 3.6% |
Questions about Immunocore Holdings plc (IMCR) stock
Who owns the most IMCR stock?
The largest reported owner of Immunocore Holdings plc (IMCR) is Wellington Management Group LLP, with 11.2% of the company. In total, 136 funds and institutions reported holding IMCR at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are IMCR insiders buying or selling?
In the last 12 months, IMCR insiders reported no open-market purchases and 10 sales worth $5.6M. The latest trade was on Feb 18, 2026. See every trade.
What is the short interest in IMCR?
As of Oct 30, 2026, 7.79M IMCR shares were sold short, 15.1% of the shares outstanding, down 0.1% from the report before. At the average daily volume of 548,595 shares, buying them all back would take about 14.2 trading days (days to cover). See the history.
Which famous investors hold IMCR?
4 of the 50 well-known investors we track reported IMCR in their latest 13F filing, including Steve Cohen, Israel Englander, Ken Griffin. The largest position is worth $38.1M. See all holders.
Executive pay
Immunocore Holdings's chief executive was paid a total of $10.9M for the year ended Dec 31, 2025, down 15% from $12.9M the year before. In the last 12 months, Immunocore Holdings's executives and directors bought no stock on the open market and sold $5.6M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.